Related references
Note: Only part of the references are listed.Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation
Vittorio Montefusco et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM)
Pamela S. Becker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gosta Gahrton et al.
BLOOD (2013)
Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation
Simona Iacobelli
BONE MARROW TRANSPLANTATION (2013)
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study
Christine Wolschke et al.
EXPERIMENTAL HEMATOLOGY (2013)
Drug safety evaluation of defibrotide
Paul G. Richardson et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy
Tereza Coman et al.
HAEMATOLOGICA (2013)
End-of-Life Care Discussions in Patients With Advanced Cancer
Pallavi Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
Henk M. Lokhorst et al.
BLOOD (2012)
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy
Soumia Touil et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
Tarun K. Garg et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
Luisa Giaccone et al.
BLOOD (2011)
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
Evelien Kneppers et al.
BLOOD (2011)
Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
L. Karlin et al.
BONE MARROW TRANSPLANTATION (2011)
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Bo Bjorkstrand et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical impact of chromosomal aberrations in multiple myeloma
H. Nahi et al.
JOURNAL OF INTERNAL MEDICINE (2011)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan et al.
LANCET ONCOLOGY (2011)
Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
N. Kroeger et al.
LEUKEMIA (2011)
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
Yvonne A. Efebera et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel et al.
BLOOD (2010)
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
Nicolaus Kroeger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Allogenic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning in Patients With Refractory and Recurrent Multiple Myeloma Long-Term Follow-Up
Avichai Shimoni et al.
CANCER (2010)
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
Antonio Palumbo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
Henk Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97
David H. Vesole et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta et al.
BLOOD (2009)
The prognostic significance of 8p21 deletion in multiple myeloma
T. Sutlu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
Constantine S. Mitsiades et al.
CLINICAL CANCER RESEARCH (2009)
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2009)
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
L. Barkholt et al.
IMMUNOTHERAPY (2009)
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma
Philippe Moreau et al.
BLOOD (2008)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Evren Alici et al.
BLOOD (2008)
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
H. de Lavallade et al.
BONE MARROW TRANSPLANTATION (2008)
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation
Francis Ayuk et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
Jean El-Cheikh et al.
HAEMATOLOGICA (2008)
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
Evren Alici et al.
EXPERIMENTAL HEMATOLOGY (2007)
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma
Gosta Gahrton et al.
HAEMATOLOGICA (2007)
Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease
F. Dignan et al.
BONE MARROW TRANSPLANTATION (2007)
Risk assessment in haematopoietic stem cell transplantation: Impact of donor-recipient sex combination in allogeneic transplantation
Gosta Gahrton
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
Ignazio Majolino et al.
LEUKEMIA & LYMPHOMA (2007)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N. W. C. J. van de Donk et al.
BONE MARROW TRANSPLANTATION (2006)
Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: Results from the Japan Myeloma Study Group
C Shimazaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma:: reduced relapse risk in female to male transplants
G Gahrton et al.
BONE MARROW TRANSPLANTATION (2005)
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC)
M Mohty et al.
BONE MARROW TRANSPLANTATION (2005)
Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma
F Ayuk et al.
LEUKEMIA (2004)
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
M Mohty et al.
BONE MARROW TRANSPLANTATION (2004)
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BLOOD (2004)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini et al.
BLOOD (2003)
Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning
H Einsele et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
CK Lee et al.
EXPERIMENTAL HEMATOLOGY (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Clinical developments in reduced intensity haematopoietic stem cell transplantation
WJ Hogan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Donor leukocyte infusions for multiple myeloma
M Salama et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
